Clinical Trials List
2022-01-14 - 2026-07-31
Phase III
Not yet recruiting1
Recruiting4
ICD-10C92.01
Acute myeloblastic leukemia, in remission
ICD-10C92.41
Acute promyelocytic leukemia, in remission
ICD-10C92.51
Acute myelomonocytic leukemia, in remission
ICD-10C92.61
Acute myeloid leukemia with 11q23-abnormality in remission
ICD-10C92.A1
Acute myeloid leukemia with multilineage dysplasia, in remission
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9205.01
Acute myeloid leukemia, in remission
xxxxxx
-
Sponsor
xxxxxx
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
Co-Principal Investigator
- 高育青 Division of Hematology & Oncology
- Yi-Chang Liu Division of Hematology & Oncology
- 柯亞倫 Division of Hematology & Oncology
- Tsung-Jang Yeh Division of Hematology & Oncology
- Jeng-Shiun Du Division of Hematology & Oncology
- Hui-Ching Wang Division of Hematology & Oncology
- Shih-Feng Cho Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Tsai-Yun Chen Division of Hematology & Oncology
- Ya-Ping Chen Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- MING YAO Division of General Internal Medicine
- Chien-Chin Lin Division of General Internal Medicine
- - - Division of General Internal Medicine
- CHENG-HONG TSAI Division of General Internal Medicine
- - - Division of General Internal Medicine
- SHAN-CHI YU Division of General Internal Medicine
- Wen-Chien Chou Division of General Internal Medicine
- 田豐銘 Division of General Internal Medicine
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Co-Principal Investigator
- Tsung -Chih Chen Division of Hematology & Oncology
- ZHENG-WEI ZHOU Division of Hematology & Oncology
- Chieh-Lin Teng Division of Hematology & Oncology
- HSIN-CHEN LIN Division of Hematology & Oncology
- CHENG-HSIEN LIN Division of Hematology & Oncology
- YU-HSUAN SHIH Division of Hematology & Oncology
- 滕傑林 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
Exclusion Criteria
The Estimated Number of Participants
-
Taiwan
12 participants
-
Global
140 participants
